Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 12/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10704353 | 0.82 | LMNA (0.32) | LMNAFDPS | |
| SCHEMBL12931443 | 0.81 | FDPS (0.48) | FDPSGGPS1 | |
| SCHEMBL2978551 | 0.80 | TSHR (0.35) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL2986483 | 0.78 | ALDH1A1 (0.33) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL871609 | 0.78 | TSHR (0.48) | LMNAFDPSTSHRALDH1A1CYP2D6 | |
| SCHEMBL1137852 | 0.78 | FDPS (0.40) | LMNAFDPSGGPS1 | |
| SCHEMBL11296652 | 0.78 | FDPS (0.50) | FDPSGGPS1 | |
| SCHEMBL11316650 | 0.76 | LMNA (0.35) | LMNAFDPSTSHRALDH1A1CYP2D6 | |
| SCHEMBL11600783 | 0.76 | TSHR (0.46) | LMNAFDPSTSHRALDH1A1CYP2D6 | |
| Butane SCHEMBL8954146 | 0.76 | FDPS (0.48) | FDPSGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554330-B1 | PARTIALLY ESTER-EXCHANGED SIPM AND PROCESS THEREWITH | INVISTA TECH SARL (CH) | 2009-03-11 | — | — | EP | claimed |
| WO-2008137446-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-11-13 | — | — | WO | claimed |
| EP-1615934-B1 | TITANIUM CHELATE DISPERSIONS | DU PONT (US) | 2007-06-27 | — | — | EP | claimed |
| CN-116926029-A | NADH dependent type L-glufosinate dehydrogenase mutant, construction method and application thereof in preparation of L-glufosinate by enzymatic method | 湖南麦肯伟科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-109735583-A | A kind of method of single transaminase-catalyzed cascade reaction asymmetric syntheses L-glufosinate-ammonium | 浙江工业大学 | 2019-05-10 | — | — | CN | disclosed |
| CN-107119084-A | A kind of method that utilization transaminase and ethylene synthetase produce L glufosinate-ammoniums | 浙江大学 | 2017-09-01 | — | — | CN | disclosed |
| CN-101336246-B | Phosphonic acid diester derivative and method for producing same | PING ZHURUN | 2012-11-28 | — | — | CN | disclosed |
| US-8129557-B2 | Phosphonic acid diester derivative and method for producing thereof | Nagai, Kazuhiro (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | HIRATAKE, GOU (JP) | 2009-06-25 | — | — | US | disclosed |
| CN-101336246-A | Phosphonic acid diester derivative and method for producing same | HIRATAKE JUN (JP) | 2008-12-31 | — | — | CN | disclosed |
| WO-2008137446-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-0290169-A2 | Diamineplatinum complexes with phosphonocarboxylate and substituted phosphonocarboxylate ligands as antitumor agents | ENGELHARD CORPORATION (US) | 1988-11-09 | — | — | EP | disclosed |
| US-4591651-A | Process for directly converting an aldehyde into an ethylene ester | AGRIFURANE S.A. (FR) | 1986-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | PPA1, G6PD, PHOSPHO1 | LMNA 3690/4885FDPS 53/4885TSHR 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.